Clinical Trial Update: Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects [Phase 2]

View source ↗

Summary

An update on a Phase 2 clinical trial evaluating an oral anti-CD3 monoclonal antibody in non-responder patients with genotype I chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Anti-CD3 Monoclonal Antibody

Snippet

Sponsor: Inspira Medical AB | Conditions: Chronic Hepatitis C | Phase 2 | Status: UNKNOWN